Publications by authors named "Yizhen Fu"

Claim this Profile
S
Social Support, Quality of Life, and Financial Toxicity Among Patients with Hepatocellular Carcinoma.
Shuyue Liu, Yawen Xie, Tiantian Li, Yanxia Huang, Danting Xu, Yizhen Fu

J Hepatocell Carcinoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study.
Li Hu, Zhoutian Yang, Zhenyun Yang, Wei Peng, Xiang Tang, Yizhen Fu

Hepatol Int· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
Mian Xi, Yizhen Fu, Yaojun Zhang

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma.
Zili Hu, Min Deng, Yizhen Fu, Zhongguo Zhou, Huanwei Chen

Int J Surg· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.
Minrui He, Wa Xie, Ze Yuan, Jinbin Chen, Juncheng Wang, Yizhen Fu

Int J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Yizhen Fu, Yaojun Zhang, Dandan Hu, Zhongguo Zhou, Li Xu

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.
Mian Xi, Zhoutian Yang, Li Hu, Yizhen Fu, Dandan Hu

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma.
Yao-Jun Zhang, Jinbin Chen, Zhongguo Zhou, Dandan Hu, Juncheng Wang, Yizhen Fu

Radiology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic changes of serum α-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma.
Zhenyun Yang, Yizhen Fu, Qianyu Wang, Yangxun Pan, Juncheng Wang

Int J Surg· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study.
Yizhen Fu, Zhoutian Yang, Shiliang Liu, Renguo Guan, Xiaohui Wang

Int J Surg· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC.
Zhenyun Yang, Qianyu Wang, Li Hu, Xiaoxian Sima, Juncheng Wang, Yizhen Fu

Front Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.
Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu

Mol Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of atezolizumab-bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study.
Zili Hu, Zhoutian Yang, Zibo Fu, Yizhen Fu, Zeliang Ma

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study.
Zhenyun Yang, Weijie Wu, Zhiwen Hu, Yizhen Fu, Zili Hu

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
Xiang Tang, Jinbin Chen, Wei Peng, Zhoutian Yang, Li Hu, Yizhen Fu

Immunotargets Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8 T cell recruitment.
Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu

Mol Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
Renguo Guan, Nan Zhang, Min Deng, Ye Lin, Guanjie Huang, Yizhen Fu

Int J Surg· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study.
Zili Hu, Xiaohui Wang, Yizhen Fu, Dinghua Yang, Zhongguo Zhou

Int J Surg· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.
Zhenyun Yang, Renguo Guan, Yizhen Fu, Dandan Hu, Zhongguo Zhou

Front Cell Infect Microbiol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.
Zili Hu, Zhiwen Hu, Weixiang Zhan, Weijie Wu, Zhongguo Zhou, Yizhen Fu

Int Immunopharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Size-Tunable Nanoregulator-Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma.
Yuhao Tang, Zhilin Shu, Meiyan Zhu, Shuping Li, Yunyan Ling, Yizhen Fu

Adv Healthc Mater· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma.
Zhenyun Yang, Yizhen Fu, Weijie Wu, Zili Hu, Yangxun Pan

Front Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.
Zili Hu, Zhenyun Yang, Jiongliang Wang, Yizhen Fu, Zhiwen Hu

Front Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma.
Zhenyun Yang, Zili Hu, Yizhen Fu, Dandan Hu, Zhongguo Zhou

J Hepatocell Carcinoma· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma.
Zili Hu, Zhenyun Yang, Yangxun Pan, Yizhen Fu, Jiongliang Wang

Front Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis